Form 4: Prelude Therapeutics Director Paul Friedman Granted Stock Options

Prelude Therapeutics Inc. Director Paul A. Friedman was granted 38,000 stock options with an exercise price of $1.04, vesting over one year or at the next annual stockholder meeting.

Summary

• Paul A. Friedman, a Director of Prelude Therapeutics Inc. (PRLD), was granted 38,000 Director Stock Options on June 12, 2025.
• The options have an exercise price of $1.04 per share.
• The options are set to expire on June 11, 2035.
• The options will fully vest upon the earlier of the Issuer's next annual stockholder meeting or the one-year anniversary of the grant date (June 12, 2026), contingent on Mr. Friedman's continued service to the Issuer.
• Following this transaction, Mr. Friedman beneficially owns 38,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive event as it aligns the director's interests with long-term shareholder value, representing a standard and expected form of compensation.

Positives

• The grant of 38,000 stock options to Director Paul A. Friedman aligns his interests with those of shareholders, incentivizing long-term company performance.
• The exercise price of $1.04 provides potential upside for the director, assuming the company's stock price appreciates above this level.

Negatives

• No direct negatives are apparent from this standard compensation filing.

Risks

• This Form 4 filing does not contain information regarding company-specific operational or financial risks.

Future Outlook

This document, a Form 4, details an insider transaction and does not provide a general future outlook or forward-looking guidance for Prelude Therapeutics Inc.

Management Comments

• This Form 4 filing does not contain direct quotes or paraphrased statements from company management.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industry, as well as other sectors, to align the interests of board members with long-term shareholder value. This particular filing reflects a routine compensation event for a director of a publicly traded company.

Comparison to Industry Standards

• The grant of stock options to a director with a vesting schedule and a specific exercise price is a standard compensation mechanism widely used across publicly traded companies, including those in the biotechnology sector like Prelude Therapeutics. While specific comparable companies or projects are not detailed in this filing, such grants are typical for board members in companies of similar size and stage.

Related Party Transactions

• The grant of 38,000 stock options to Paul A. Friedman, a Director of Prelude Therapeutics Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns their interests with shareholders, potentially encouraging decisions that enhance long-term share value. However, future exercise of these options could lead to minor dilution.
• Employees: No direct impact on employees is mentioned in this filing.
• Customers/Suppliers/Creditors: No direct impact on customers, suppliers, or creditors is mentioned in this filing.

Next Steps

• The granted options will vest upon the earlier of Prelude Therapeutics Inc.'s next annual stockholder meeting or the one-year anniversary of the grant date (June 12, 2026), subject to Paul A. Friedman's continued provision of service to the Issuer.

Key Dates

Keywords

Prelude Therapeutics, PRLD, stock options, insider transaction, Form 4, director compensation, equity grant, Paul Friedman